RecruitingPhase IFemale onlyEN original
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT04427293Original on ClinicalTrials.gov ↗
⚠️
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is single arm study of a window of opportunity in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive lenvatinib 12 mg daily for 7 and pembrolizumab 200 mg IV on day 1 prior to surgery
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histologicznie rak piersi (niedrobnokomórkowy), stadium T1b-T3, N0-N3, M0
- •Kandydat do operacyjnego leczenia radykalnego
- •Dostępna próbka tkanki z biopsji do badań
- •Planowana operacja usunięcia guza i węzłów chłonnych po chemioterapii przedoperacyjnej
- •Rak potrójnie ujemny (brak receptorów estrogenowych, progesteronowych i HER2)
- •Zadowalająca funkcja narządów wewnętrznych (wątroba, nerki, krew)
- •Brak przerzutów odległych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- December 16, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
University of Illinois
Chicago, United States
Trial contact
Oana Danciu, MD
Prathmika Jha, BS
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.